N-cadherin expression was reduced, and E-cadherin expression increased in combination-treated ovarian cancer cells compared to those in the control and single-agent groups, consistent with previous research (Haslehurst et al., 2012; Wang et al., 2014). Here, CDH2 is linked to ovarian carcinoma.